Related Experiment Video
Updated: Jan 3, 2026

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
Targeting senescent cells in translational medicine
Marta Paez-Ribes1, Estela González-Gualda1, Gary J Doherty2
1Department of Oncology, CRUK Cambridge Centre Early Detection Programme, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK.
Abstract:
Organismal ageing is a complex process driving progressive impairment of functionality and regenerative potential of tissues. Cellular senescence is a state of stable cell cycle arrest occurring in response to damage and stress and is considered a hallmark of ageing. Senescent cells accumulate in multiple organs during ageing, contribute to tissue dysfunction and give rise to pathological manifestations. Senescence is therefore a defining feature of a variety of human age-related disorders, including cancer, and targeted elimination of these cells has recently emerged as a promising therapeutic approach to ameliorate tissue damage and promote repair and regeneration. In addition, in vivo identification of senescent cells has significant potential for early diagnosis of multiple pathologies. Here, we review existing senolytics, small molecules and drug delivery tools used in preclinical therapeutic strategies involving cellular senescence, as well as probes to trace senescent cells. We also review the clinical research landscape in senescence and discuss how identifying and targeting cellular senescence might positively affect pathological and ageing processes.
Related Concept Videos
Replicative Cell Senescence
Targeted Cancer Therapies
There are several types of targeted therapies against...
iPS Cell Differentiation

